{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:48:01Z","timestamp":1790225281260,"version":"4.1.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82450111"],"award-info":[{"award-number":["82450111"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373416"],"award-info":[{"award-number":["82373416"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82388102"],"award-info":[{"award-number":["82388102"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82525052"],"award-info":[{"award-number":["82525052"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017003","name":"Peking University Health Science Center","doi-asserted-by":"publisher","award":["BMU2025BSS001"],"award-info":[{"award-number":["BMU2025BSS001"]}],"id":[{"id":"10.13039\/501100017003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007937","name":"Peking University","doi-asserted-by":"publisher","award":["RDL2023-10"],"award-info":[{"award-number":["RDL2023-10"]}],"id":[{"id":"10.13039\/501100007937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005090","name":"Beijing Nova Program","doi-asserted-by":"publisher","award":["20240484580"],"award-info":[{"award-number":["20240484580"]}],"id":[{"id":"10.13039\/501100005090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.canlet.2026.218743","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T15:02:30Z","timestamp":1784559750000},"page":"218743","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Circular RNA-based therapeutic vaccine elicits potent antigen-specific antitumor immunity and remodels tumor microenvironment in lung cancer"],"prefix":"10.1016","volume":"658","author":[{"given":"Shaoyi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zewen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kezhong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0419-9139","authenticated-orcid":false,"given":"Mantang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218743_bib1","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-CT013","article-title":"Abstract CT013: phase I trial evaluating BNT116, a TAA-encoding mRNA vaccine, in combination with cemiplimab in frail patients with advanced non-small cell lung cancer (NSCLC)","volume":"85","author":"Dziadziuszko","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218743_bib2","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2026.218743_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.691","article-title":"N1-methylpseudouridine modification level correlates with protein expression, immunogenicity, and stability of mRNA","volume":"5","author":"Chen","year":"2024","journal-title":"MedComm"},{"key":"10.1016\/j.canlet.2026.218743_bib4","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.molcel.2017.05.022","article-title":"Sensing self and foreign circular RNAs by Intron identity","volume":"67","author":"Chen","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2026.218743_bib5","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nsmb.2943","article-title":"Toll-like receptor 8 senses degradation products of single-stranded RNA","volume":"22","author":"Tanji","year":"2015","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.canlet.2026.218743_bib6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41586-023-06800-3","article-title":"N(1)-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting","volume":"625","author":"Mulroney","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218743_bib7","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41576-019-0158-7","article-title":"The biogenesis, biology and characterization of circular RNAs","volume":"20","author":"Kristensen","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.canlet.2026.218743_bib8","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jconrel.2022.05.043","article-title":"Circular RNA: an emerging frontier in RNA therapeutic targets, RNA therapeutics, and mRNA vaccines","volume":"348","author":"Liu","year":"2022","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.canlet.2026.218743_bib9","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.7536344","article-title":"Initiation of protein synthesis by the eukaryotic translational apparatus on circular RNAs","volume":"268","author":"Chen","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.canlet.2026.218743_bib10","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1261\/rna.072611.119","article-title":"Metabolic labeling of RNA uncovers the contribution of transcription and decay rates on hypoxia-induced changes in RNA levels","volume":"26","author":"Tiana","year":"2020","journal-title":"RNA"},{"key":"10.1016\/j.canlet.2026.218743_bib11","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1038\/s41467-018-05096-6","article-title":"Engineering circular RNA for potent and stable translation in eukaryotic cells","volume":"9","author":"Wesselhoeft","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218743_bib12","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41587-019-0090-6","article-title":"Highly efficient expression of circular RNA aptamers in cells using autocatalytic transcripts","volume":"37","author":"Litke","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.canlet.2026.218743_bib13","doi-asserted-by":"crossref","first-page":"6422","DOI":"10.7150\/thno.77350","article-title":"Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies","volume":"12","author":"Li","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2026.218743_bib14","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2302191120","article-title":"Circular RNA vaccine induces potent T cell responses","volume":"120","author":"Amaya","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2026.218743_bib15","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/resp.12789","article-title":"Immunotherapy for lung cancer","volume":"21","author":"Steven","year":"2016","journal-title":"Respirology"},{"key":"10.1016\/j.canlet.2026.218743_bib16","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","article-title":"Combination strategies to maximize the benefits of cancer immunotherapy","volume":"14","author":"Zhu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2026.218743_bib17","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218743_bib18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ymthe.2017.10.020","article-title":"Combination immunotherapy of MUC1 mRNA nano-vaccine and CTLA-4 blockade effectively inhibits growth of triple negative breast cancer","volume":"26","author":"Liu","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2026.218743_bib19","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ymthe.2017.11.009","article-title":"mRNA vaccine with antigen-specific checkpoint blockade induces an enhanced immune response against established melanoma","volume":"26","author":"Wang","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2026.218743_bib20","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines: advancements, challenges, and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218743_bib21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41577-024-01091-9","article-title":"Vax-Innate: improving therapeutic cancer vaccines by modulating T cells and the tumour microenvironment","volume":"25","author":"Baharom","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2026.218743_bib22","article-title":"A universal strategy of anti-tumor mRNA vaccine by harnessing \"Off-the-Shelf\" immunity","volume":"12","author":"Fu","year":"2025","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.canlet.2026.218743_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1792","article-title":"Restoring expression of tumour suppressor PTEN by engineered circular RNA-enhanced Osimertinib sensitivity in non-small cell lung cancer","volume":"14","author":"Li","year":"2024","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218743_bib24","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41419-019-1744-5","article-title":"Roles of circular RNAs in immune regulation and autoimmune diseases","volume":"10","author":"Zhou","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2026.218743_bib25","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.cell.2019.03.046","article-title":"Structure and degradation of circular RNAs regulate PKR activation in innate immunity","volume":"177","author":"Liu","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218743_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd9882","article-title":"Triple-modality therapy maximizes antitumor immune responses in a mouse model of mesothelioma","volume":"13","author":"Murakami","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218743_bib27","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2400153121","article-title":"An IL-23-STAT4 pathway is required for the proinflammatory function of classical dendritic cells during CNS inflammation","volume":"121","author":"Alakhras","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2026.218743_bib28","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/sj.emboj.7600085","article-title":"Runx3 regulates mouse TGF-beta-mediated dendritic cell function and its absence results in airway inflammation","volume":"23","author":"Fainaru","year":"2004","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2026.218743_bib29","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.ccell.2024.08.019","article-title":"Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer","volume":"42","author":"Wang","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218743_bib30","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4161\/adip.26220","article-title":"The immune cell transcription factor T-bet: a novel metabolic regulator","volume":"3","author":"Stolarczyk","year":"2014","journal-title":"Adipocyte"},{"key":"10.1016\/j.canlet.2026.218743_bib31","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.4049\/jimmunol.169.8.4388","article-title":"Activated STAT4 has an essential role in Th1 differentiation and proliferation that is independent of its role in the maintenance of IL-12R beta 2 chain expression and signaling","volume":"169","author":"Nishikomori","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2026.218743_bib32","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1126\/science.1074900","article-title":"Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection","volume":"297","author":"Nguyen","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.canlet.2026.218743_bib33","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nature24993","article-title":"Runx3 programs CD8(+) T cell residency in non-lymphoid tissues and tumours","volume":"552","author":"Milner","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218743_bib34","doi-asserted-by":"crossref","first-page":"7817","DOI":"10.4049\/jimmunol.0802527","article-title":"The Runx3 transcription factor augments Th1 and down-modulates Th2 phenotypes by interacting with and attenuating GATA3","volume":"183","author":"Kohu","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2026.218743_bib35","article-title":"METTL3\/ALKBH5-Mediated N6-Methyladenosine modification drives macrophage M1 polarization via the SLC15A3-TASL-IRF5 signaling axis in psoriasis","author":"Huang","year":"2025","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.canlet.2026.218743_bib36","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/CAD.0000000000001582","article-title":"NFATc2 promotes lactate and M2 macrophage polarization through USP17 in lung adenocarcinoma","volume":"35","author":"Wang","year":"2024","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.canlet.2026.218743_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25074117","article-title":"Tumor and peritoneum-associated macrophage gene signature as a novel molecular biomarker in gastric cancer","volume":"25","author":"Sullivan","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218743_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2023.166852","article-title":"Cancer-associated fibroblasts drive early pancreatic cancer cell invasion via the SOX4\/MMP11 signalling axis","volume":"1870","author":"Ge","year":"2024","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.canlet.2026.218743_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112666","article-title":"EBF1-COX4I2 signaling axis promotes a myofibroblast-like phenotype in cancer-associated fibroblasts (CAFs) and is associated with an immunosuppressive microenvironment","volume":"139","author":"Li","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.canlet.2026.218743_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2025.09.001","article-title":"Single-cell resolution spatial analysis of antigen-presenting cancer-associated fibroblast niches","author":"Chen","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218743_bib41","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2026.218743_bib42","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1002\/ijc.35088","article-title":"The current therapeutic cancer vaccines landscape in non-small cell lung cancer","volume":"155","author":"Chen","year":"2024","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218743_bib43","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218743_bib44","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218743_bib45","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41392-023-01561-x","article-title":"Circular RNA vaccine in disease prevention and treatment","volume":"8","author":"Niu","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218743_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114826","article-title":"Clinical delivery of circular RNA: lessons learned from RNA drug development","volume":"197","author":"Loan Young","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.canlet.2026.218743_bib47","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.720","article-title":"Synthetic circRNA therapeutics: innovations, strategies, and future horizons","volume":"5","author":"Cai","year":"2024","journal-title":"MedComm"},{"key":"10.1016\/j.canlet.2026.218743_bib48","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.cell.2022.03.044","article-title":"Circular RNA vaccines against SARS-CoV-2 and emerging variants","volume":"185","author":"Qu","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218743_bib49","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1084\/jem.187.2.265","article-title":"Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes","volume":"187","author":"J\u00e4ger","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2026.218743_bib50","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1073\/pnas.94.5.1914","article-title":"A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening","volume":"94","author":"Chen","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2026.218743_bib51","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.lungcan.2008.12.020","article-title":"Spontaneous remission of a non-small cell lung cancer possibly caused by anti-NY-ESO-1 immunity","volume":"65","author":"Nakamura","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canlet.2026.218743_bib52","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00262-020-02483-1","article-title":"First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors","volume":"69","author":"Ishihara","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2026.218743_bib53","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1158\/1078-0432.CCR-03-0245","article-title":"NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors","volume":"10","author":"Maraskovsky","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218743_bib54","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1002\/ijc.25955","article-title":"A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen","volume":"129","author":"Kakimi","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218743_bib55","doi-asserted-by":"crossref","first-page":"eaaz6893","DOI":"10.1126\/sciadv.aaz6893","article-title":"Impact of mRNA chemistry and manufacturing process on innate immune activation","volume":"6","author":"Nelson","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2026.218743_bib56","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2026.218743_bib57","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.molcel.2019.02.015","article-title":"RNA circularization diminishes immunogenicity and can extend translation duration in vivo","volume":"74","author":"Wesselhoeft","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2026.218743_bib58","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.molcel.2019.07.016","article-title":"N6-Methyladenosine modification controls circular RNA immunity","volume":"76","author":"Chen","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2026.218743_bib59","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.molcel.2021.11.019","article-title":"RNA circles with minimized immunogenicity as potent PKR inhibitors","volume":"82","author":"Liu","year":"2022","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2026.218743_bib60","doi-asserted-by":"crossref","first-page":"eadn9961","DOI":"10.1126\/sciadv.adn9961","article-title":"Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity","volume":"10","author":"Fan","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2026.218743_bib61","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s00535-015-1078-8","article-title":"NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers","volume":"51","author":"Oshima","year":"2016","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.canlet.2026.218743_bib62","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13046-022-02307-3","article-title":"Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade","volume":"41","author":"Bai","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218743_bib63","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.03224-20","article-title":"Development of DNA vaccine targeting E6 and E7 proteins of human papillomavirus 16 (HPV16) and HPV18 for immunotherapy in combination with recombinant Vaccinia boost and PD-1 antibody","volume":"12","author":"Peng","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.canlet.2026.218743_bib64","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/ijc.34267","article-title":"Phase 1 trial of CV301 in combination with anti-PD-1 therapy in nonsquamous non-small cell lung cancer","volume":"152","author":"Rajan","year":"2023","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218743_bib65","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","article-title":"A phase Ib trial of personalized neoantigen therapy plus Anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer","volume":"183","author":"Ott","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218743_bib66","first-page":"499","article-title":"Revolutionizing tumor immunotherapy: unleashing the power of progenitor exhausted T cells","volume":"21","author":"Fang","year":"2024","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.canlet.2026.218743_bib67","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","article-title":"Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts","volume":"9","author":"Elyada","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218743_bib68","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/s41467-025-57465-7","article-title":"Antigen-presenting cancer associated fibroblasts enhance antitumor immunity and predict immunotherapy response","volume":"16","author":"Song","year":"2025","journal-title":"Nat. Commun."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526005070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526005070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:43:19Z","timestamp":1788482599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526005070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":68,"alternative-id":["S0304383526005070"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218743","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circular RNA-based therapeutic vaccine elicits potent antigen-specific antitumor immunity and remodels tumor microenvironment in lung cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218743","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"218743"}}